Emergent BioSolutions Inc. reported second quarter 2025 financial results, with revenues exceeding the top end of its guidance by $21 million. The company announced it is raising the low end and midpoint of its full-year 2025 profitability guidance, reflecting strong execution of its multi-year transformation plan.
For Q2 2025, Emergent reported a net loss of $12 million, or $0.22 per share, with adjusted earnings of $0.16 per share. While Naloxone revenues decreased by 44% and Anthrax MCM revenues decreased by 70%, Smallpox MCM revenues increased significantly by 127%, driven by VIGIV CNJ-016 sales timing.
Year-to-date, Emergent has secured seven biodefense contract modifications, demonstrating its leadership in medical countermeasures with the U.S. government and allied stakeholders. The company remains confident in its full-year guidance and expects a strong second half of the year, driven by sustained demand for naloxone products and an encouraging outlook in its medical countermeasures business.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.